All4Nutra
Pharmatrans excipients for improved compactibility and flowability in tablet manufacture
Study of rheological and tableting properties of lubricated mixtures of co-processed dry binders for orally disintegrating tablets
Pharmatrans adds SANAQ® SP205 and SP206 to Direct Compression excipients range
Comparison of Flow and Compression Properties of Four Lactose-Based Co-Processed Excipients: Cellactose® 80, CombiLac®, MicroceLac® 100, and StarLac®
Monitoring of high-load dose formulations based on co-processed and non co-processed excipients
![Application of SeDeM Expert System in particle engineering design space of co-processed excipients. Stage I involves the characterization of Critical Material Attributes (CMAs) of both defective and corrective materials using SeDeM methodology [a]. Stage II: Computing the loading capacity of the corrective excipient using dilution potential equation proposed by the SeDeM Expert System [b]. Stage III: Selection of co-processing technique based on intrinsic material property and desired CMAs [c]. Stage IV: Evaluating the impact of co-processing by monitoring the critical behavior of the engineered composite with the decision on either to accept or reject the product [d]. Upon failing to meet up with the critical specifications or acceptance criteria, the process conditions in Stage III can be revalidated or modified. IPP: Parametric Profile Index, IGC: Good Compression Index, ψc: Compressibility function, ѱf: Flowability function](https://www.pharmaexcipients.com/wp-content/uploads/2021/07/Application-of-SeDeM-Expert-System-in-the-development-of-novel-directly-compressible-co-processed-ex-600x279.jpg)
